Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysisHuseyin Naci, Christopher M. Booth, Xochitl Romo-Sandoval et al.|BMJ|2019Cited by 242